Cellectis

Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.

CRISPR is the paradigm now in research applications, but companies with IP rights to TALENs and zinc finger nucleases are pushing forward with those technologies.

The technology is for gene targeting using endocunleases and homologous recombination, and is the second licensing deal between the parties since April.

Cellectis, Janssen, and others plunge into cell therapy with the help of several genome-editing technologies, including TALENs and CRISPR/Cas9.

The firm adds CRISPR/Cas9 gene editing to its portfolio of plant genome engineering technologies, which also includes meganucleases and TALENs.

Based in New York, the subsidiary will feature laboratory space to develop the firm's chimeric antigen receptor T cells for cancer immunotherapy.

The gene editing company priced its initial public offering of 5.5 million American Depositary Shares with expectations of going public on the Nasdaq. 

The arrangement covers Cellectis' TALEN technology and Two Blades' TAL effector code technology.

NEW YORK (GenomeWeb) – Cellectis today announced it is selling its stem cell-focused subsidiary Cellectis AB to Takara Bio for an undisclosed amount.

NEW YORK (GenomeWeb) – Thermo Fisher Scientific and French firm Cellectis have inked a series of agreements covering the use of TAL nucleases for a variety of applications.

Pages

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.